What happened with MMSI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Merit Medical Systems supplies devices that physicians use to access blood vessels, examine them and perform treatments such as angioplasty and stent placement. Products used in procedures performed through the skin generate much of its revenue. Its cardiovascular business accounts for most sales, including devices for peripheral blood vessels and the heart, along with kits that bring together supplies for a procedure.
Hospitals and outpatient facilities buy these products directly from Merit or through distributors and other suppliers. Merit also sells components and finished devices to other medical-device manufacturers, which can incorporate them into their own offerings. A smaller endoscopy business supplies devices for digestive and lung procedures.
The United States provides most revenue. China is its largest market outside the United States, where distributors mainly resell products to hospitals. China’s volume-based procurement policy has reduced Merit’s selling prices and revenue there.
Purchasing depends in part on government and private insurers covering procedures that use Merit’s devices. In the United States, new devices and new claims for existing devices generally require FDA clearance or approval. Merit cannot promote its products for uses that have not been cleared or approved.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Merit's results hinge on demand for interventional procedures and competition with privately held Cook Medical, a major rival in peripheral intervention, cardiac intervention, oncology and endoscopy.
Boston Scientific competes with Merit for hospitals' and specialist physicians' purchases of cardiac, peripheral-intervention and endoscopy devices. Its sales in these areas offer a read on procedure demand shared with Merit, alongside competition for those purchases.
Teleflex competes with Merit to supply hospitals and healthcare providers with single-use devices for cardiac and peripheral interventions. Watch its product launches in these areas: device performance and cost-effectiveness are among the factors Teleflex says determine competition.
AngioDynamics competes with Merit for clinicians' use of interventional catheters, vascular-access and drainage products, and devices for vascular disease and cancer. Its new products in these areas are worth watching because AngioDynamics says growth depends substantially on new introductions and enhancements.
Penumbra and Merit compete to sell physicians devices that block blood vessels or provide access into them for treatment—embolization and vascular-access technologies. Penumbra's embolization and access sales are the relevant demand signal for Merit, rather than its separate thrombectomy market.
Becton, Dickinson and Co. (BD) competes with Merit for healthcare providers' purchases of peripheral-intervention, cardiac-intervention and oncology devices. Its Interventional business is the part to watch for this overlap, rather than its wider laboratory and medical-supplies businesses.
Medtronic competes with Merit in cardiac and peripheral-intervention devices supplied to healthcare providers, as well as Merit's smaller spine-device business. Its new devices in these fields matter more for assessing Merit's competition than its diabetes products.
Abbott competes with Merit for cardiac-intervention device purchases, but its much broader healthcare business makes its overall results a less direct comparison. Watch its cardiac-intervention devices rather than its branded generic medicines sold in emerging markets outside the United States.
TriSalus Life Sciences competes with Merit's Swift NINJA microcatheter through TriNav, which it sells to U.S. hospitals and ambulatory surgery centers for radiologists performing embolization procedures. TriNav revenue grew 53.4% to $45.2 million in 2025, a concrete measure of adoption of this competing product, used most commonly for primary liver cancer and liver metastases.
Boston Scientific Corp. earningsBSX
Boston Scientific's report will show how hospitals and specialist physicians are buying the cardiac, peripheral-intervention and endoscopy devices it shares with Merit Medical, amid competition for those purchases.
Focus on Boston Scientific's cardiac, peripheral-intervention and endoscopy sales—not its company-wide results—and compare their direction with Merit Medical's corresponding product sales. Strength at both points to robust demand for shared procedures; Boston Scientific gaining while Merit weakens in those products points to a shift in purchases toward a competitor; weakness at both points to softer shared demand.
Merit Medical Systems Inc earningsThis company
Merit Medical's report will show whether hospitals and other buyers are still driving sales growth, and whether better pricing and product mix can keep higher costs from eroding its gross margin.
Read sales growth alongside gross margin, the share of sales left after product costs. Growing sales with a stable or higher margin would show that buyers are ordering more and pricing or product mix is keeping cost pressure in check. Growing sales with a falling margin would show that higher production costs or customer price concessions are eating into the growth.
